B6.Cg-Tg(Pklr-BCL2)BAk/Orl
| Status | Available to order |
| EMMA ID | EM:05819 |
| International strain name | B6.Cg-Tg(Pklr-BCL2)BAk/Orl |
| Alternative name | LPK-Bcl-2 |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(Pklr-BCL2)BAk, |
| Gene/Transgene symbol | Tg(Pklr-BCL2)BAk |
Information from provider
| Provider | Helene Gilgenkrantz |
| Provider affiliation | Endocrinology Metabolism Cancer, Institut Cochin INSERM U567 |
| Genetic information | Additive transgenic mouse strain expressing the human Bcl-2 cDNA under the regulatory sequences of the rat L-pyruvate kinase promoter. The expression of the transgene is mainly in the liver, kidney and intestine and weakly in pancreas. |
| Phenotypic information | No phenotype at quiescent stage but a protection against liver apoptosis, ischemia reperfusion lesions and mitochondrial dysfunction. |
| Breeding history | More than 30 backcrosses to C57BL/6 background. |
| References |
|
| Homozygous fertile | not known |
| Homozygous viable | not known |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
| Animals used for archiving | heterozygous C57BL/6J, wild-type C57BL/6J |
Literature references
- Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice.;Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T, Porteu A, Henrion A, Bouscary D, Varlet P, Joulin V, Kahn A, ;1996;Nature medicine;2;80-6; 8564847
- Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes.;Mignon A, Guidotti J E, Mitchell C, Fabre M, Wernet A, De La Coste A, Soubrane O, Gilgenkrantz H, Kahn A, ;1998;Nature medicine;4;1185-8; 9771754
- Bone marrow transplantation in mice leads to a minor population of hepatocytes that can be selectively amplified in vivo.;Mallet Vincent O, Mitchell Claudia, Mezey Eva, Fabre Monique, Guidotti Jacques-Emmanuel, Renia Laurent, Coulombel Laure, Kahn Axel, Gilgenkrantz Hélène, ;2002;Hepatology (Baltimore, Md.);35;799-804; 11915025
- The combination of ischemic preconditioning and liver Bcl-2 overexpression is a suitable strategy to prevent liver and lung damage after hepatic ischemia-reperfusion.;Peralta Carmen, Perales José Carlos, Bartrons Ramón, Mitchell Claudia, Gilgenkrantz Hélène, Xaus Carme, Prats Neus, Fernández Leticia, Gelpí Emilio, Panés Julia, Roselló-Catafau Juan, ;2002;The American journal of pathology;160;2111-22; 12057915
- Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice.;Mitchell Claudia, Robin Marie-Anne, Mayeuf Alicia, Mahrouf-Yorgov Meriem, Mansouri Abdellah, Hamard Marie, Couton Dominique, Fromenty Bernard, Gilgenkrantz Hélène, ;2009;The American journal of pathology;175;1929-37; 19808650
- Overexpression of Bcl-2 in hepatocytes protects against injury but does not attenuate fibrosis in a mouse model of chronic cholestatic liver disease.;Mitchell Claudia, Mahrouf-Yorgov Meriem, Mayeuf Alicia, Robin Marie-Anne, Mansouri Abdellah, Fromenty Bernard, Gilgenkrantz Hélène, ;2011;Laboratory investigation; a journal of technical methods and pathology;91;273-82; 20856227